

KAREN L. CRUEY, M. D.
PSYCHIATRIC MEDICINE

Specialist in
• Child and Adolescent
• Adult Psychiatry
Psychotherapy
Independent Medical Evaluations

2340 Paseo del Prado, D303
Las Vegas, NV 89102
(702) 247-1703
Fax (702) 247-4082
administrative cellular (702)219-4584

May 28, 2021

Pharmacy and Therapeutics Committee
State of Nevada Department of Health and Human Services
Division of Health Care Financing and Policy
1100 E. William Street, Suite 101
Carson City, NV 89701

Re: Agenda Item 6D, Annual Review-Established Drug Classes Being Reviewed
due to Release of New Drugs – Psychotropic Agents: Antipsychotics: Atypical
Antipsychotics –oral

To Whom It May Concern:

I understand that Nevada Medicaid will review oral atypical antipsychotics for
the Preferred Drug List at the June 24, 2021 Therapeutics Committee meeting. I
request that the committee add Caplyta (lumateperone) to the State of
Nevada Formulary for schizophrenia.

I have used Caplyta in my patients with schizophrenia, with excellent outcome.
A young male adult special needs patient has had much calmer demeanor, no
longer hitting his care provider, now sleeping well for the first time in months, and
with an increase in speaking where previously he spoke little.

Thank you in advance for adding this important new medication to the State of
Nevada Formulary.

Respectfully submitted,



Karen L. Cruey, M.D.
Adult, Adolescent & Child Psychiatry
Nevada Medical License 8506